Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
accepted:
21
06
2022
pubmed:
16
7
2022
medline:
3
8
2022
entrez:
15
7
2022
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Saudi Arabia was significantly impacted by COVID-19. In March 2021, 381,000 cases were reported with 6539 deaths. This study attempts to quantify the impact of remdesivir on healthcare costs in Saudi Arabia, in terms of intensive care unit admissions, mechanical ventilation, and death prevention. A forecasting model was designed to estimate the impact of remdesivir on the capacity of intensive care units and healthcare costs with patients requiring low flow oxygen therapy. The forecasting model was applied in the Saudi context with a 20-week projection between 1 February and 14 June, 2021. Model inputs were collected from published global and Saudi literature, available forecasting resources, and expert opinions. Three scenarios were assumed: the effective pandemic infection rate (Rt) remains at 1, the Rt increases up to 1.2, and the Rt declines from 1 to 0.8 over the study period. The model estimated that the use of remdesivir in hospitalized patients, in the optimistic and pessimistic scenarios, could prevent between 1520 and 3549 patient transfers to intensive care units and mechanical ventilation, prevent between 815 and 1582 deaths, and make potential cost savings between $US154 million and $US377 million owing to the reduction in intensive care unit capacity, respectively. The treatment with remdesivir may improve patient outcomes and reduce the burden on healthcare resources during this pandemic.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Saudi Arabia was significantly impacted by COVID-19. In March 2021, 381,000 cases were reported with 6539 deaths. This study attempts to quantify the impact of remdesivir on healthcare costs in Saudi Arabia, in terms of intensive care unit admissions, mechanical ventilation, and death prevention.
METHODS
METHODS
A forecasting model was designed to estimate the impact of remdesivir on the capacity of intensive care units and healthcare costs with patients requiring low flow oxygen therapy. The forecasting model was applied in the Saudi context with a 20-week projection between 1 February and 14 June, 2021. Model inputs were collected from published global and Saudi literature, available forecasting resources, and expert opinions. Three scenarios were assumed: the effective pandemic infection rate (Rt) remains at 1, the Rt increases up to 1.2, and the Rt declines from 1 to 0.8 over the study period.
RESULTS
RESULTS
The model estimated that the use of remdesivir in hospitalized patients, in the optimistic and pessimistic scenarios, could prevent between 1520 and 3549 patient transfers to intensive care units and mechanical ventilation, prevent between 815 and 1582 deaths, and make potential cost savings between $US154 million and $US377 million owing to the reduction in intensive care unit capacity, respectively.
CONCLUSIONS
CONCLUSIONS
The treatment with remdesivir may improve patient outcomes and reduce the burden on healthcare resources during this pandemic.
Identifiants
pubmed: 35838880
doi: 10.1007/s40261-022-01177-z
pii: 10.1007/s40261-022-01177-z
pmc: PMC9284952
doi:
Substances chimiques
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
669-678Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Havrlant D, Darandary A, Muhsen A. Early estimates of the impact of the COVID-19 pandemic on GDP: a case study of Saudi Arabia. Appl Econ. 2021;53(12):1317–25.
doi: 10.1080/00036846.2020.1828809
International Monetary Fund (IMF). IMF reports and publications by country: gross domestic product, constant prices. https://www.imf.org/en/Data . Accessed 23 Apr 2021.
Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus pandemic (COVID-19). https://ourworldindata.org . Accessed 16 May 2022.
Algaissi AA, Alharbi NK, Hassanain M, Hashem AM. Preparedness and response to COVID-19 in Saudi Arabia: building on MERS experience. J Infect Public Health. 2020;13(6):834–8.
doi: 10.1016/j.jiph.2020.04.016
Alahmari AA, Khan AA, Elganainy A, Almohammadi EL, Hakawi AM, Assiri AM, et al. Epidemiological and clinical features of COVID-19 patients in Saudi Arabia. J Infect Public Health. 2021;14(4):437–43.
doi: 10.1016/j.jiph.2021.01.003
Ministry of Health (MoH). Saudi MoH protocol for patients suspected of/confirmed with COVID-19. MoH. 2021. https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf . Accessed 15 Apr 2022.
US Food and Drug Administration (FDA). EUA approval. Reissued Oct. 22nd, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 . Accessed 2 Nov 2021.
European Medicines Agency (EMA). Veklury (remdesivir): an overview of Veklury and why it is authorised in the EU. EMA/676677. 23 June, 2020. https://www.ema.europa.eu/en/documents/overview/veklury-epar-medicine-overview_en.pdf . Accessed 23 Apr 2021.
Saudi Food & Drug Authority (SFDA). 2021. https://www.sfda.gov.sa/en/drugs-list . Accessed 27 Nov 2021.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19: final report. N Engl J Med. 2020;383:1813–26.
doi: 10.1056/NEJMoa2007764
Ruggeri M, Signorini A, Drago C, Rosiello F, Marchetti M. Modello di stima dei costi sanitari e della capacity delleterapie intensive in Italia nel trattamento di pazienti affetti da COVID-19: valutazione dell’impatto di remdesivir. AboutOpen. 2020;7(1):95–102.
doi: 10.33393/abtpn.2020.2213
Ruggeri M, Signorini A, Caravaggio S, Rua J, Luìs N, Braz S, et al. Estimation model for healthcare costs and intensive care units access for Covid-19 patients and evaluation of the effects of remdesivir in the Portuguese context: hypothetical study. Clin Drug Investig. 2022;42:345–54. https://doi.org/10.1007/s40261-022-01128-8 .
doi: 10.1007/s40261-022-01128-8
pubmed: 35298832
pmcid: 8928238
Epiforecast. 2021. https://www.epiforecasts.io/ . Accessed 22 Mar 2021.
Al-Omari A, Alhuqbani WN, Zaidi ARZ, Al-Subaie MF, AlHindi AM, Abogosh AK, et al. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: a descriptive cross-sectional study. J Infect Public Health. 2021;13:1639–44.
doi: 10.1016/j.jiph.2020.09.003
Khan AA, AlRuthia Y, Balkhi B, Alghadeer SM, Temsah M-H, Althunayyan SM, Alsofayan YM. Survival and estimation of direct medical costs of hospitalized COVID-19 patients in the Kingdom of Saudi Arabia. Int J Environ Res Public Health. 2020;17(20):7458. https://doi.org/10.3390/ijerph17207458 .
doi: 10.3390/ijerph17207458
pmcid: 7602112
Badreddine SA, Zammo M, Elhosiny AA, Alhomsy MW, Aldabbagh Y, Mansouri AS, et al. Clinical course and outcome of 395 Covid 19 patients admitted to one hospital in Jeddah, Saudi Arabia. Int J Infect Dis Ther. 2021;5(4):118–26.
Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K, et al. Clinical characteristics and predictors of 28-day mortality in 352 critically ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health. 2021;11(1):98–104.
doi: 10.2991/jegh.k.200928.001
AlSulaiman KA, Aljuhani O, Eljaaly K, Alharbi AA, Al Shabasy AM, Alsaeedi AS, et al. Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): a multicenter cohort study. Int J Infect Dis. 2021;105:180–7.
doi: 10.1016/j.ijid.2021.02.037
Alqahtani AM, AlMalki ZS, Alalweet RM, Almazrou SH, Alanazi AS, Alanazi MA, et al. Assessing the severity of illness in patients with coronavirus disease in Saudi Arabia: a retrospective descriptive cross-sectional study. Front Public Health. 2020;8: 593256.
doi: 10.3389/fpubh.2020.593256
Gilead Sciences, Inc. An open letter from Daniel O’Day, Chairman & CEO, Gilead Sciences. 29 June, 2020. https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/an-open-letter-from-daniel-oday-chairman--ceo-gilead-sciences . Accessed 20 Apr 2021.
Gubrium JF, Holstein JA. Handbook of interview research: context & method. Thousand Oaks: Sage Publications, Inc.; 2001.
doi: 10.4135/9781412973588
Patton MQ. How to use qualitative methods in evaluation. Centre for Study of Evaluation, University of California, Los Angeles, California, USA. Thousand Oaks: Sage Publications, Inc.; 1987.
Gostic KM, McGough L, Baskerville EB, Abbott S, Joshi K, Tedijanto C, et al. Practical considerations for measuring the effective reproductive number. Rt Open Access. 2020. https://doi.org/10.1371/journal.pcbi.1008409 .
doi: 10.1371/journal.pcbi.1008409
WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Open Access. 2022;399(10399):P1941–53. https://doi.org/10.1016/S0140-6736(22)00519-0 .
doi: 10.1016/S0140-6736(22)00519-0
Jeck J, Jakobs F, Kron A, Franz J, Cornely OA, Kron F. A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic “first wave” in a German tertiary care hospital. Infection. 2022;50(1):191–201. https://doi.org/10.1007/s15010-021-01685-8 .
doi: 10.1007/s15010-021-01685-8
pubmed: 34406606
Béraud G, Timsit JF, Leleu H. Remdesivir as a tool to relieve hospital care systems stressed by COVID-19: a modelling study on bed resources and budget impact. medRxiv. 2021. https://doi.org/10.1101/2021.02.24.21252355 .
Jo Y, Jamieson L, Edoka I, Long L, Silal S, Pulliam JRC, et al. Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. medRxiv. 2020. https://doi.org/10.1101/2020.09.24.20200196 (Update in: Open Forum Infect Dis. 2021;8(3):ofab040 PMID: 32995824; PMCID: PMC7523165).
Oksuz E, Malhan S, Gonen MS, Kutlubay Z, Keskindemirci Y, Jarrett J, et al. Cost-effectiveness analysis of remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey. Adv Ther. 2021. https://doi.org/10.1007/s12325-021-01874-9 .
doi: 10.1007/s12325-021-01874-9
pubmed: 34379304
pmcid: 8355577